Trial Parameters
Brief Summary
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years) * Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies * Patients have provided written informed consent Exclusion Criteria: * Persons under guardianship or curatorship * Persons under legal protection, * Persons persons deprived of liberty * Persons not affiliated to a social security scheme * Pregnant or breastfeeding women